Reuters logo
10 个月前
BRIEF-Coherus Biosciences says FDA acceptance of 351(K) biologics license application
2016年10月6日 / 晚上10点07分 / 10 个月前

BRIEF-Coherus Biosciences says FDA acceptance of 351(K) biologics license application

1 分钟阅读

Oct 6 (Reuters) - Coherus Biosciences

* Announces FDA Acceptance Of 351(K) Biologics License Application to U.S. Food And Drug Administration for CHS-1701 (pegfilgrastim biosimilar candidate)

* Biosimilar User Fee Act (BSUFA) action date is June 9, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below